Contact Us

special ASH update

TEXT SIZE

print share |

12.17.06   Long Term Results of a Study of Rev/Dex in Newly Diagnosed Patients
	Martha Q. Lacy, MD Mayo Clinic Rochester, MN

---

12.17.06   Long-Term Follow-Up of a Phase II Trial of Vel/Dex in Frontline Therapy for Myeloma
	Sundar Jagannath, MD St. Vincent’s Comprehensive Cancer Center New York, NY

---

12.17.06   Phase I/II Study of Revlimid + Melphalan/Prednisone (R-MP) for Newly Diagnosed Myeloma
	Antonio Palumbo, MD Ospedale Molinette Torino, Italy

---

12.17.06   Relationship Between Quality of Response to Velcade and Clinical Benefit
	Ruben Niesvizky, MD New Presbyterian Hospital Weill Cornell Medical Center New York, NY

---

12.17.06   Revlimid-Induced Myelosuppression is Potentially Associated with Renal Dysfunction in Treatment-Naïve MM Patients Receiving BiRD
	Ruben Niesvizky, MD New Presbyterian Hospital Weill Cornell Medical Center New York, NY

---

12.17.06   The Use of Lenalidomide +/- Dexamethasone in Patients with AL Amyloidosis
	Angela Dispenzieri, MD Mayo Clinic Rochester, MN

---

12.17.06   The Use of Velcade + Melphalan/Prednisone in Elderly Non-Transplant Patients
	Jesús San Miguel, MD Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain

---

12.17.06   The Use of Velcade as First-Line Therapy in High-Risk Myeloma
	Angela Dispenzieri, MD Mayo Clinic Rochester, MN

---

12.17.06   Use of Revlimid With or Without Steroids in Relapsed/Refractory Myeloma Patients with Elevated Baseline Serum Creatinine
	Donna E. Reece, MD Princess Margaret Hospital Toronto, Canada

---

12.17.06   Velcade and Doxil as Induction Therapy for Newly Diagnosed Myeloma
	Robert Z. Orlowski, MD Lineberger Cancer Center University of North Carolina Chapel Hill, NC

---